EUVIMEDEUVIMED entdecken
Klinische Studie

Evaluation of a novel skin care product for the management of chemotherapy–related dermatologic toxicities: A quasi-experimental study

Jolien Robijns, Joy Lodewijckx, Marithé Claes, Laura Tuts, Melissa Lenaerts, Tim Wessels, Annelies Requilé, Daisy Luyten, Jolanda Verheezen, Eric Joosens, Jeroen Mebis

European Journal of Oncology Nursing · 2023

DOI: 10.1016/j.ejon.2023.102278 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Oncology Nursing, 2023. Verfasst von Jolien Robijns und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. Electronic ad…. Hauptthemen laut MEDLINE: Emollients, Skin Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Limburg Sterk Merk, Universiteit Hasselt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Evaluate the efficacy of a novel skincare product for the management of chemotherapy-related dermatological toxicities. METHODS: A monocentric, prospective, interventional, open-label, pretest-posttest, single-group study with cancer patients receiving chemotherapy (n = 100) was set up. All enrolled patients applied the emollient daily to their face and body for three weeks. The severity of the skin reactions was evaluated by a researcher using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at baseline and end of the trial. Patient-reported outcomes (PROs) included the frequency and severity of skin symptoms (Numerical rating scale, NRS), quality of life (QoL; Skindex-16 and Dermatology Life Quality Index), Patient Benefit Index (PBI), and treatment satisfaction. PROs were collected at baseline, weekly, and at the end of the trial. RESULTS: According to the CTCAE and NRS, the novel emollient significantly improved the severity and frequency of xerosis and pruritus (Ps ≤ .001). A significant reduction in the NRS score for frequency of erythema was measured (p < .001). The frequency and severity of burning and pain did not change. Regarding the patients' QoL, no beneficial effect of the skin care product was measurable. 44% of the patients experienced at least one patient-relevant treatment benefit. 87% of the patients were satisfied with the emollient and would recommend it. CONCLUSIONS: This study shows that the novel emollient significantly reduced chemotherapy-induced skin toxicity, more specifically xerosis and pruritus without hampering patient's QoL. Future research is needed to make definite conclusions using a study design including a control group and a long-term follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EmollientsSkin DiseasesHumansProspective StudiesPruritusQuality of LifeSkin Care

Stichwörter der Autor:innen

CancerChemotherapyEmollientOncologySkin careSkin toxicity

Substanzen

Emollients

Autor:innen und Institutionen

  • Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium. Electronic address: Jolien.Robijns@uhasselt.be.
  • Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium.
  • Faculty of Health, Medicine and Life Sciences, Department of Surgery, GROW School for Oncology & Reproduction, Maastricht University, Universiteitssingel 50, 6229ER, Maastricht, Netherlands.
  • Limburg Oncology Center, Jessa Hospital, Stadsomvaart 11, 3500, Hasselt, Belgium.
  • Faculty of Medicine and Life Sciences, Limburg Clinical Research Center, Hasselt University, Martelarenlaan 42, 3500, Hasselt, Belgium; Limburg Oncology Center, Jessa Hospital, Stadsomvaart 11, 3500, Hasselt, Belgium.

Förderung

  • Limburg Sterk Merk
  • Universiteit Hasselt

Zitieren

APA

Robijns, J., Lodewijckx, J., Claes, M., Tuts, L., Lenaerts, M., Wessels, T., Requilé, A., Luyten, D., Verheezen, J., Joosens, E., & Mebis, J. (2023). Evaluation of a novel skin care product for the management of chemotherapy–related dermatologic toxicities: A quasi-experimental study. European Journal of Oncology Nursing. https://doi.org/10.1016/j.ejon.2023.102278

Vancouver

Robijns J, Lodewijckx J, Claes M, Tuts L, Lenaerts M, Wessels T, et al. Evaluation of a novel skin care product for the management of chemotherapy–related dermatologic toxicities: A quasi-experimental study. European Journal of Oncology Nursing. 2023. doi:10.1016/j.ejon.2023.102278

BibTeX
@article{Robijns2023,
  author = {Robijns, Jolien and Lodewijckx, Joy and Claes, Marithé and Tuts, Laura and Lenaerts, Melissa and Wessels, Tim and Requilé, Annelies and Luyten, Daisy and Verheezen, Jolanda and Joosens, Eric and Mebis, Jeroen},
  title = {Evaluation of a novel skin care product for the management of chemotherapy–related dermatologic toxicities: A quasi-experimental study},
  journal = {European Journal of Oncology Nursing},
  year = {2023},
  doi = {10.1016/j.ejon.2023.102278}
}
Kostenlos starten →